newsfilter
← Latest News
GlobeNewswire·

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World